S&N Shares Offer Value for the Long Run

Smith & Nephew's shares have retreated due to economic, regulatory, and reimbursement risks, but the long-term outlook remains good

Julie Stralow, CFA 25 August, 2011 | 3:50PM
Facebook Twitter LinkedIn

Smith & Nephew (SN.) shares appear to be trading below our worst-case valuation scenario primarily due to rising economic uncertainty. The firm focuses on relatively young, active patients, putting it on the front line of cyclical downturns. However, we think Smith & Nephew's unique strategy of pursuing relatively young, active patients should serve the firm well, producing volume growth and perhaps protecting prices if the reimbursement landscape changes substantially in the long run.

Smith & Nephew faces tough competitors in its chosen fields, but we think its devices offer compelling value propositions. The firm operates in three medical device niches: orthopedic implants, arthroscopy tools, and advanced wound management.

This is an excerpt from the Morningstar Analyst Report on Smith & Nephew. Read the full report here. Morningstar Research is available to Premium subscribers. Find out more about Premium here.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
Smith & Nephew PLC1,157.00 GBX0.87Rating

About Author

Julie Stralow, CFA  Julie Stralow, CFA, is a senior securities analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures